IL278618A - - Google Patents
Info
- Publication number
- IL278618A IL278618A IL27861820A IL27861820A IL278618A IL 278618 A IL278618 A IL 278618A IL 27861820 A IL27861820 A IL 27861820A IL 27861820 A IL27861820 A IL 27861820A IL 278618 A IL278618 A IL 278618A
- Authority
- IL
- Israel
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862671521P | 2018-05-15 | 2018-05-15 | |
| PCT/EP2019/062305 WO2019219658A1 (en) | 2018-05-15 | 2019-05-14 | Treatment of cancer |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| IL278618A true IL278618A (https=) | 2021-01-31 |
| IL278618B1 IL278618B1 (en) | 2025-07-01 |
| IL278618B2 IL278618B2 (en) | 2025-11-01 |
Family
ID=66752041
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL278618A IL278618B2 (en) | 2018-05-15 | 2019-05-14 | Treatment of cancer |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US12209126B2 (https=) |
| EP (1) | EP3793607A1 (https=) |
| JP (2) | JP7531404B2 (https=) |
| KR (1) | KR102885515B1 (https=) |
| CN (1) | CN112203691A (https=) |
| AU (2) | AU2019270277B9 (https=) |
| CA (1) | CA3099820A1 (https=) |
| EA (1) | EA202092696A1 (https=) |
| IL (1) | IL278618B2 (https=) |
| MA (1) | MA52627A (https=) |
| SG (1) | SG11202011117VA (https=) |
| TW (1) | TW202011989A (https=) |
| WO (1) | WO2019219658A1 (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG10202007781TA (en) | 2014-09-16 | 2020-09-29 | Innate Pharma | Treatment Regimens Using Anti-NKG2A Antibodies |
| WO2019175182A1 (en) | 2018-03-13 | 2019-09-19 | Innate Pharma | Treatment of head and neck cancer |
| CN113583127A (zh) * | 2020-04-30 | 2021-11-02 | 迈威(上海)生物科技股份有限公司 | 一种靶向nkg2a和pd-l1的双特异性抗体及应用 |
| CN116096754A (zh) * | 2020-05-04 | 2023-05-09 | 免疫里森公司 | 前体三特异性抗体构建体及其使用方法 |
| CN115516086A (zh) * | 2020-05-13 | 2022-12-23 | 南京传奇生物科技有限公司 | 类猿icp47及变体减少同种异体细胞宿主排斥的组合物及方法 |
| WO2023284874A1 (zh) * | 2021-07-16 | 2023-01-19 | 克莱格医学有限公司 | 用于肿瘤免疫学的组合物和方法 |
| PE20241475A1 (es) * | 2021-10-04 | 2024-07-17 | Servier Lab | Terapia del cancer dirigida a nkg2a |
| JP2025500845A (ja) * | 2021-12-14 | 2025-01-15 | ユニバーシティ オブ ピッツバーグ －オブ ザ コモンウェルス システム オブ ハイヤー エデュケイション | Ｃｄ９４／ｎｋｇ２ａヘテロ二量体ポリペプチドに結合する分子 |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5567610A (en) | 1986-09-04 | 1996-10-22 | Bioinvent International Ab | Method of producing human monoclonal antibodies and kit therefor |
| US5229275A (en) | 1990-04-26 | 1993-07-20 | Akzo N.V. | In-vitro method for producing antigen-specific human monoclonal antibodies |
| ATE483472T1 (de) | 2002-05-30 | 2010-10-15 | Macrogenics Inc | Cd16a bindungsproteine und verwendung zur behandlung von immunkrankheiten |
| PT1831258E (pt) | 2004-12-28 | 2016-01-07 | Univ Genova | Anticorpos monoclonais contra nkg2a |
| DK2439273T3 (da) | 2005-05-09 | 2019-06-03 | Ono Pharmaceutical Co | Humane monoklonale antistoffer til programmeret død-1(pd-1) og fremgangsmåder til behandling af cancer ved anvendelse af anti-pd-1- antistoffer alene eller i kombination med andre immunterapeutika |
| PT1907424E (pt) | 2005-07-01 | 2015-10-09 | Squibb & Sons Llc | Anticorpos monoclonais humanos para o ligando 1 de morte programada (pd-l1) |
| MX2008015830A (es) | 2006-06-30 | 2009-01-09 | Novo Nordisk As | Anticuerpos anti-nkg2a y usos de los mismos. |
| BR122017025062B8 (pt) | 2007-06-18 | 2021-07-27 | Merck Sharp & Dohme | anticorpo monoclonal ou fragmento de anticorpo para o receptor de morte programada humano pd-1, polinucleotídeo e composição compreendendo o referido anticorpo ou fragmento |
| KR20100110864A (ko) | 2008-01-24 | 2010-10-13 | 노보 노르디스크 에이/에스 | 인간화된 항-인간 ｎｋｇ2ａ 모노클로날 항체 |
| EP3255060A1 (en) | 2008-12-09 | 2017-12-13 | F. Hoffmann-La Roche AG | Anti-pd-l1 antibodies and their use to enhance t-cell function |
| PL2504364T3 (pl) | 2009-11-24 | 2017-12-29 | Medimmune Limited | Ukierunkowane środki wiążące przeciwko B7-H1 |
| EP3409289B1 (en) | 2010-02-26 | 2020-09-30 | Novo Nordisk A/S | Stable antibody containing compositions |
| KR102047248B1 (ko) | 2011-06-17 | 2019-11-21 | 노보 노르디스크 에이/에스 | 침식성 세포의 선택적 제거 |
| RU2017105425A (ru) * | 2014-08-28 | 2018-09-28 | Академиш Зикенхёйс Лейден Х.О.Д.Н. Люмк | Комбинации антитела против cd94/nkg2a и/или cd94/nkg2b и вакцины |
| AU2015316991B2 (en) | 2014-09-16 | 2021-04-01 | Innate Pharma | Neutralization of inhibitory pathways in lymphocytes |
| SG10202007781TA (en) | 2014-09-16 | 2020-09-29 | Innate Pharma | Treatment Regimens Using Anti-NKG2A Antibodies |
| US10329348B2 (en) | 2014-10-23 | 2019-06-25 | Innate Pharma | Treatment of cancers using anti-NKG2A agents |
| ES2986067T3 (es) * | 2015-12-17 | 2024-11-08 | Novartis Ag | Moléculas de anticuerpos frente a PD-1 y usos de las mismas |
| SI3405495T1 (sl) | 2016-01-21 | 2021-08-31 | Innate Pharma | Nevtralizacija inhibitornih poti v limfocitih |
| WO2019175182A1 (en) | 2018-03-13 | 2019-09-19 | Innate Pharma | Treatment of head and neck cancer |
-
2019
- 2019-05-14 EA EA202092696A patent/EA202092696A1/ru unknown
- 2019-05-14 CN CN201980031725.8A patent/CN112203691A/zh active Pending
- 2019-05-14 JP JP2020563542A patent/JP7531404B2/ja active Active
- 2019-05-14 AU AU2019270277A patent/AU2019270277B9/en active Active
- 2019-05-14 IL IL278618A patent/IL278618B2/en unknown
- 2019-05-14 WO PCT/EP2019/062305 patent/WO2019219658A1/en not_active Ceased
- 2019-05-14 TW TW108116510A patent/TW202011989A/zh unknown
- 2019-05-14 SG SG11202011117VA patent/SG11202011117VA/en unknown
- 2019-05-14 MA MA052627A patent/MA52627A/fr unknown
- 2019-05-14 KR KR1020207035232A patent/KR102885515B1/ko active Active
- 2019-05-14 CA CA3099820A patent/CA3099820A1/en active Pending
- 2019-05-14 EP EP19728320.3A patent/EP3793607A1/en active Pending
- 2019-05-14 US US17/054,920 patent/US12209126B2/en active Active
-
2024
- 2024-04-03 JP JP2024059910A patent/JP2024102055A/ja active Pending
-
2025
- 2025-01-14 AU AU2025200275A patent/AU2025200275A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CA3099820A1 (en) | 2019-11-21 |
| SG11202011117VA (en) | 2020-12-30 |
| CN112203691A (zh) | 2021-01-08 |
| TW202011989A (zh) | 2020-04-01 |
| MA52627A (fr) | 2021-03-24 |
| WO2019219658A1 (en) | 2019-11-21 |
| KR20210010486A (ko) | 2021-01-27 |
| JP2024102055A (ja) | 2024-07-30 |
| AU2025200275A1 (en) | 2025-01-30 |
| KR102885515B1 (ko) | 2025-11-12 |
| US12209126B2 (en) | 2025-01-28 |
| IL278618B2 (en) | 2025-11-01 |
| EP3793607A1 (en) | 2021-03-24 |
| AU2019270277B9 (en) | 2024-12-05 |
| AU2019270277B2 (en) | 2024-11-21 |
| EA202092696A1 (ru) | 2021-04-05 |
| JP7531404B2 (ja) | 2024-08-09 |
| IL278618B1 (en) | 2025-07-01 |
| JP2021523170A (ja) | 2021-09-02 |
| US20210253694A1 (en) | 2021-08-19 |
| AU2019270277A1 (en) | 2021-01-07 |